PMID- 15372222
OWN - NLM
STAT- MEDLINE
DCOM- 20050324
LR  - 20181201
IS  - 0941-4355 (Print)
IS  - 0941-4355 (Linking)
VI  - 12
IP  - 12
DP  - 2004 Dec
TI  - Rapid administration of ibandronate does not affect renal functioning: evidence 
      from clinical studies in metastatic bone disease and hypercalcaemia of 
      malignancy.
PG  - 877-81
AB  - Ibandronate is a third-generation aminobisphosphonate that has an excellent 
      safety record in hypercalcaemia of malignancy, and has recently been approved for 
      the prevention of skeletal events from metastatic breast cancer. This paper 
      reviews the safety data from clinical studies of intravenous ibandronate by 
      infusion or injection, focusing on renal adverse events (AEs). In clinical trials 
      of patients with hypercalcaemia of malignancy, 2-h infusions of ibandronate at 
      doses of up to 6 mg had a low potential for renal events. In a phase III trial of 
      patients with metastatic bone disease from breast cancer, 6 mg ibandronate 
      infused over 1-2 h had a renal safety profile comparable to that of placebo. In 
      pilot studies, repeated daily infusions of ibandronate (4 mg infused over 2 h for 
      four consecutive days, or 6 mg infused over 1 h for three consecutive days) for 
      severe metastatic bone pain were not associated with any renal AEs. The safety of 
      single 15-min infusions of 6 mg ibandronate has been demonstrated in healthy 
      volunteers and patients with metastatic bone disease from breast cancer or 
      multiple myeloma. Furthermore, single and rapid bolus injections of 2 or 3 mg 
      ibandronate did not increase the risk of renal dysfunction in patients with 
      skeletal metastases. Implications for the renal safety of ibandronate in the 
      management of patients with metastatic bone disease are discussed.
FAU - Pecherstorfer, M
AU  - Pecherstorfer M
AD  - First Department of Medicine and Oncology, Wilhelminenspital, Montleartstrasse 
      37, 1171, Vienna, Austria. martin.pecherstorfer@wienkav.at
FAU - Diel, I J
AU  - Diel IJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20040915
PL  - Germany
TA  - Support Care Cancer
JT  - Supportive care in cancer : official journal of the Multinational Association of 
      Supportive Care in Cancer
JID - 9302957
RN  - 0 (Diphosphonates)
RN  - UMD7G2653W (Ibandronic Acid)
SB  - IM
MH  - Bone Neoplasms/*drug therapy/*secondary
MH  - Breast Neoplasms/*pathology
MH  - Diphosphonates/*administration & dosage/adverse effects
MH  - Female
MH  - Humans
MH  - Hypercalcemia/*drug therapy
MH  - Ibandronic Acid
MH  - Infusions, Intravenous
MH  - Injections, Intravenous
MH  - Kidney Diseases/*chemically induced
RF  - 30
EDAT- 2004/09/17 05:00
MHDA- 2005/03/25 09:00
CRDT- 2004/09/17 05:00
PHST- 2004/02/09 00:00 [received]
PHST- 2004/06/01 00:00 [accepted]
PHST- 2004/09/17 05:00 [pubmed]
PHST- 2005/03/25 09:00 [medline]
PHST- 2004/09/17 05:00 [entrez]
AID - 10.1007/s00520-004-0655-9 [doi]
PST - ppublish
SO  - Support Care Cancer. 2004 Dec;12(12):877-81. doi: 10.1007/s00520-004-0655-9. Epub 
      2004 Sep 15.